Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has commenced a Phase 3 pivotal clinical trial to investigate AD04 as a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder (AUD). The trial has initially started in Finland, where Adial previously announced it had received approval to commence the trial. The trial is also expected to be conducted in Sweden, Poland, Latvia, Estonia, Croatia, and Bulgaria. Adial has filed clinical trial applications (CTAs) to also conduct the trial in each of these countries where additional trial sites will be initiated on a country-by-country basis following each CTA approval.
Crown CRO becomes part of the Optimapharm family
We are very excited to announce the acquisition of Crown […]
Crown CRO and Medical Writer Ada MacKeith part of University of Helsinki HITP group mentoring programme
In 2019 the University of Helsinki launched the HelsinkiUNI International […]
We are seeking a Medical Writing Document Manager in Finland
Crown CRO Oy is looking for a Medical Writing Document […]
ADIAL: The Phase 3 ONWARD™ trial meets its screening target and nears enrollment completion
July 6, 2021 Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) announced […]
Promising results from clinical trial for the treatment of Celiac Disease
Dr. Falk Pharma GmbH and Zedira GmbH have announced successful […]